NetScientific (STU:NTK1) Gross-Profit-to-Asset % : 5.56% (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is NetScientific Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. NetScientific's annualized Gross Profit for the quarter that ended in Jun. 2023 was €1.67 Mil. NetScientific's average Total Assets over the quarter that ended in Jun. 2023 was €30.07 Mil. Therefore, NetScientific's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 5.56%.

NetScientific Gross-Profit-to-Asset % Historical Data

The historical data trend for NetScientific's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetScientific Gross-Profit-to-Asset % Chart

NetScientific Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

1.74

9.54

4.75

7.00

3.12

NetScientific Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															4.57	5.44	3.70	3.55	5.56

Competitive Comparison of NetScientific's Gross-Profit-to-Asset %

For the Biotechnology subindustry, NetScientific's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NetScientific's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NetScientific's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where NetScientific's Gross-Profit-to-Asset % falls into.

NetScientific Gross-Profit-to-Asset % Calculation

NetScientific's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	0.899	/	( (24.352	+	33.291)	/ 2 )
	=	0.899	/	28.8215
	=	3.12 %

NetScientific's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	1.672	/	( (33.291	+	26.854)	/ 2 )
	=	1.672	/	30.0725
	=	5.56 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

NetScientific Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of NetScientific's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

NetScientific (STU:NTK1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NetScientific PLC (STU:NTK1) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

NSCI:UK

Address

20 Saint Andrew Street, Holborn Circus, London, GBR, EC4A 3AG

Website

https://www.netscientific.net

NetScientific PLC is a transatlantic healthcare technology company. The group is focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients, Glucosense a provider of a non-invasive glucose monitoring wearable device, Vortex Biosciences which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing, and Glycotest which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis.

NetScientific (STU:NTK1) Headlines

No Headlines